SILAC proteomics analysis to discover effect sensors of EGFR inhibition
收藏NIAID Data Ecosystem2026-03-10 收录
官方服务：
资源简介：
Targeted therapies against EGFR show clinical benefit, but resistance to these agents invariably develops. Thus, there is a need for dynamic biomarkers - effect sensors - that reflect treatment with EGFR therapeutics during therapy. Making use of SILAC-labeling we aimed to discover plasma membrane proteins that become differentially expressed after treatment with EGFR inhibitor erlotinib in three erlotinib-sensitive breast cancer cell lines.
创建时间：
2018-10-18
